PT - JOURNAL ARTICLE AU - MUTTIAH BARATHAN AU - AHMAD KHUSAIRY ZULPA AU - KUMUTHA MALAR VELLASAMY AU - VANITHA MARIAPPAN AU - NAVEEN KUMAR HAWALA SHIVASHEKAREGOWDA AU - ZARIDATUL AINI IBRAHIM AU - JAMUNA VADIVELU TI - Cytotoxic Activity of Isoniazid Derivative in Human Breast Cancer Cells AID - 10.21873/invivo.12551 DP - 2021 Sep 01 TA - In Vivo PG - 2675--2685 VI - 35 IP - 5 4099 - http://iv.iiarjournals.org/content/35/5/2675.short 4100 - http://iv.iiarjournals.org/content/35/5/2675.full SO - In Vivo2021 Sep 01; 35 AB - Background/Aim: Isoniazid is an antibiotic used for the treatment of tuberculosis. Previously, we found that the isoniazid derivative (E)-N’-(2,3,4-trihydroxybenzylidene) isonicotinohydrazide (ITHB4) could be developed as novel antimycobacterial agent by lead optimization. We further explored the ability of this compound compared to zerumbone in inhibiting the growth of MCF-7 breast cancer cells. Materials and Methods: Cytotoxicity was measured by the MTT assay and further confirmed via apoptosis, ROS, cell cycle, DNA fragmentation and cytokine assays. Results: ITHB4 demonstrated a lower IC50 compared to zerumbone in inhibiting the proliferation of MCF-7 cells. ITHB4 showed no toxicity against normal breast and human immune cells. Apoptosis assay revealed that ITHB4, at a concentration equal to the IC50, induces apoptosis of MCF-7 cells and cell cycle arrest at the sub-G1 and G2/M phases. ITHB4 triggered accumulation of intracellular ROS and nuclear DNA fragmentation. Secretion of pro-inflammatory cytokines induced inflammation and potentially immunogenic cell death. Conclusion: ITHB4 has almost similar chemotherapeutic properties as zerumbone in inhibiting MCF-7 growth, and hence provide the basis for further experiments in animal models.